On 24th September 2019, the first volunteer was enrolled in the IAVI-W001 study at the KAVI-Institute of Clinical Research (KAVI-ICR) of the University of Nairobi.  The occasion marks the beginning of the 12th HIV vaccine clinical trial to be conducted at KAVI-ICR since 2001. This is a first-in-human study that uses a Native-trimer HIV envelope design that will hopefully stimulate broadly neutralizing antibodies against HIV.